![Novartis HQ](https://pharmaphorum.com/wp-content/uploads/2017/06/Novartis-HQ.jpg)
ASCO21: Novartis' prostate cancer radiotherapy extends survi...
Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options li